Union Chimique Belge (UCB)
UCB is a biopharmaceutical company founded in 1928 with its headquarters at Belgium (Brussels). It has a revenue turnover of 3.3 billion Euros and mainly focuses on Research and development (R&D). It manufactures various medicines for Epilepsy, Crohn’s disease and Parkinson’s disease and focuses on UCB customer service. The main focus of the company is on treatments for many diseases that are treated by specialists in the fields of Central Nervous System (CNS) disorders, oncology and inflammatory disorders. In order to promote research in neuroscience, the company presents UCB award for every 3 years. As per 2014 report, the company has over 8,500 employees operating in about 40 countries and has 2 research centres in UK and Belgium.
UCB’s Products
All around the world, the medicines of UCB makes a real difference when compared with others. UCB provides an amazing UCB customer service to patients that wonder them as how a pharmaceutical company can show such an interest and affection towards patients. Their main products are divided into two categories: Immunology and Neurology. Products in Immunology can help in treating axial spondyloarthritis, Crohn’s disease, Psoriatic Arthritis, Rheumatoid Arthritis. Similarly, products in Neurology can be used to treat Epilepsy (Vimpat, Keppra), Parkinson’s disease (Neupro) and restless leg syndrome (Neupro).
UCB Investor Relations
UCB customer service is always very happy to answer questions from its customers or patients. Isabelle, Antje and Nathalie as a part of UCB customer service answers every question posted by the customers. In order to contact Antje Witte (VP Investor Relations), customers can call at: +32 2 559 9414 or can e-mail at: Antje.Witte@ucb.com. Isabelle Ghellynck (Associate Director Investor Relations) can be contacted through Tel: +32 2 559 9588 or through e-mail: Isabelle.Ghellynck@ucb.com. Also, Nathalie Deldime (Investor Relations Events Manager) can be contacted at Tel: +32 2 559 9291 and at Nathalie. Deldime@ucb.com.
Contact IR Team
Investor Relations team can be directly contacted through phone: + 32 2 559 9291 or through FAX: +32 2 559 9571 or through e-mail: investor-relations@ucb.com. UCB customer service reception can be contacted directly through Tel: +32 2 559 9999. However, UCB customer service provides customers to be in touch with the company in twitter, facebook, LinkedIn, YouTube through its feed. Any other queries can be directly written to the address: Allee De la Recherche 60, 1070 Brussels, Belgium. However, patients should contact their health care providers for personal health concerns.
